Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 518, Issue 2, 2002, Pages 181-194

  Suter, Willi ^a   Hartmann, Andreas ^a   Poetter, Franziska ^a   Sagelsdorff, Peter ^b   Hoffmann, Peter ^a   Martus, Hans Jörg ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b JEALOTT S HILL RESEARCH STATION   (United Kingdom)

Author keywords

Antiepileptic; Comet assay; DNA binding; Muta Mouse; Nitroaromatic compound; Nitroreductase

Indexed keywords

AMP 397; ANTICONVULSIVE AGENT; AROMATIC NITRO COMPOUND; CARBON 14; NITROREDUCTASE; UNCLASSIFIED DRUG; ((7 NITRO 2,3 DIOXO 1,4 DIHYDROQUINOXALIN 5 YL)METHYLAMINO)METHYLPHOSPHONIC ACID; ((7-NITRO-2,3-DIOXO-1,4-DIHYDROQUINOXALIN-5-YL)METHYLAMINO)METHYLPHOSPHONIC ACID; QUINOXALINE DERIVATIVE;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; BONE MARROW CELL; CELL STRAIN V 79; COLON; COMET ASSAY; CONTROLLED STUDY; DRUG DNA BINDING; FEMALE; GENOTOXICITY; IN VITRO STUDY; JEJUNUM; LIVER; MALE; MAMMAL CELL; MAXIMUM TOLERATED DOSE; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RAT; SALMONELLA TYPHIMURIUM; TOXICITY TESTING; WILD TYPE; ANIMAL; CELL CULTURE; CRICETULUS; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GENETICS; HAMSTER; LEUKEMIA L 5178 Y; LIVER MICROSOME; METABOLISM; MOUSE MUTANT; PATHOLOGY; STRUCTURE ACTIVITY RELATION; WISTAR RAT;

MAMMALIA; MUS; RATTUS; SALMONELLA TYPHIMURIUM;

ANIMALS; ANTICONVULSANTS; BONE MARROW CELLS; COMET ASSAY; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; JEJUNUM; LEUKEMIA L5178; LIVER; MALE; MICE; MICE, MUTANT STRAINS; MICRONUCLEUS TESTS; MICROSOMES, LIVER; QUINOXALINES; RATS; RATS, WISTAR; SALMONELLA TYPHIMURIUM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 33846359284     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(02)00105-5     Document Type: Article

References (52)

1. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342 (2000) 314-319
2. Fischer R.S., Vickrey B.G., Gibson P., Hermann B., Penovich P., Scherer A., and Walker S. The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions. Epilepsy Res. 41 (2000) 39-51
3. Fischer R.S., Vickrey B.G., Gibson P., Hermann B., Penovich P., Scherer A., and Walker S. The impact of epilepsy from the patient's perspective II: views about therapy and health care. Epilepsy Res. 41 (2000) 53-61
4. Tortorella A., Halonen T., Sahibzada N., and Gale K. A crucial role of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype of glutamate receptors in piriform and perirhinal cortex for the initiation and propagation of limbic motor seizures. J. Pharmacol. Exp. Ther. 280 (1997) 1401-1405
5. Katsumori H., Mibabe Y., Osawa M., and Ashby Jr. R. Acute effect of various GABA receptor agonists and glutamate antagonists on focal hippocampal seizures in freely moving rats elicited by low-frequency stimulation. Synapse 28 (1998) 103-109
6. Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog. Neurobiol. 54 (1998) 721-741
7. Nakahara W., Fukuoka F., and Sugimuira T. Carcinogenic action of 4-nitro-quinoline-1-oxide. Gann 48 (1957) 129-137
8. Purohit V., and Basu A.K. Mutagenicity of nitroaromatic compounds. Chem. Res. Toxicol. 13 (2000) 673-692
9. S.M. Cohen, Toxicity and carcinogenicity of nitrofurans, in: G.T. Bryan (Ed.), Carcinogenesis, Vol 4, Nitrofurans, Raven Press, New York, 1978, pp. 171-231.
10. Dobias L., Cerna M., Roessner P., and Sram R. Genotoxicity and carcinogenicity of metronidazole. Mutation Res. 317 (1994) 177-194
11. Pfau W., Pool-Zobel B.L., von der Lieth C.-W., and Wiessler M. The structural basis for the mutagenicity of aristolochia acid. Cancer Lett. 55 (1990) 7-11
12. Howard P.C., Heflich R.H., Evans F.E., and Beland F.A. Formation of DNA adducts in vitro and in Salmonella typhimurium upon metabolic reduction of the environmental mutagen 1-nitropyrene. Cancer Res. 43 (1983) 2052-2058
13. Pederson T.C., and Siak J.S. The activation of mutagens in diesel particle extract with rat liver S9 enzymes. J. Appl. Toxicol. 1 (1981) 61-66
14. Tocher J.H. Reductive activation of nitroheterocyclic compounds. Gen. Pharmac. 28 (1997) 485-487
15. Ashby J., and Tennant R.W. Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP. Mutation Res. 204 (1988) 17-115
16. Korbelik M., and Horvat D. The mutagenicity of nitroaromatic drugs. Effect of metronidazole after incubation in hypoxia in vitro. Mutation Res. 78 (1980) 201-207
17. Thornton-Manning J.R., Smith B.A., Beland F.A., and Heflich F.L. S9-mediated metabolism of 1-nitropyrene to a mutagen in chinese hamster ovary cells by ring-oxidation under aerobic conditions and by nitroreduction under anaerobic condition. Carcinogenesis 12 (1991) 43-51
18. Maron M., and Ames B.N. Revised methods for the Salmonella mutagenicity tests. Mutation Res. 113 (1983) 173-215
19. OECD guideline for testing of chemicals, Nr. 471, genetic toxicology: bacterial reverse mutation test, adopted 21 July 1997.
20. Rosenkranz E.J., McCoy E.C., Mermelstein R., and Rosenkranz H.S. Evidence for the existence of distinct nitroreductases in S. typhimurium: roles in mutagenesis. Carcinogenesis 3 (1982) 121-123
21. Miller B., Albertini S., Locher F., Thybaud V., and Lorge E. Comparative evaluation of the in vitro micronucleus test and the in vitro chromosome aberration test: industrial experience. Mutation Res. 392 (1997) 45-59
22. J. Cole, D.B. Mc Gregor, M. Fox, R.C. Garner, J. Thacker, Gene mutation assay in cultured mammalian cells, in: D.J. Kirkland (Ed.), Basic mutagenicity tests UKEMS recommended procedures, Cambridge University Press, Cambridge, 1990, pp. 87-114.
23. OECD. Guideline for testing of chemicals, 476, genetic toxicology: in vitro mammalian cell gene mutation tests, adopted 21 July 1997.
24. W.D. Robinson, M.H.L. Green, J. Cole, R.C. Garner, M.J.R. Healy, D. Gatehouse, Statistical evaluation of bacterial/mammalian fluctuation tests, in: D.J. Kirkland (Ed.), Statistical evaluation of mutagenicity test data, Cambridge University Press, Cambridge, 1990, pp. 102-140.
25. Romagna F., and Staniforth C.D. The automated bone marrow micronucleus test. Mutation Res. 213 (1989) 91-104
26. OECD guideline for the testing of chemicals, 474, genetic toxicology: mammalian erythrocyte micronucleus test, adopted 21 July 1997.
27. Frieauff W., and Romagna F. Technical aspects of automatic micronucleus analysis in rodent bone marrow assays. Cell Biol. Toxicol. 10 (1994) 283-289
28. BigBlue™ transgenic mouse mutagenesis assay system (stratagene, 1 May 1994).
29. - plasmids. Nucl. Acid Res. 20 (1992) 3254
30. - phage using a galactose-sensitive E. coli host. Biotechniques 14 (1993) 326-330
31. Muta™mouse: mutation assay instruction manual (Covance Hazleton, version obtained on 15 July 1996).
32. Speit G., and Hartmann A. The comet assay (single-cell gel test)-A sensitive genotoxicity test for the detection of DNA damage and repair. DNA Repair Protocols 113 (1999) 203-212
33. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.-C., and Sasaki Y.F. The single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35 (2000) 206-221
34. Frieauff W., Hartmann A., and Suter W. Automatic analysis of slides processed in the comet assay. Mutagenesis 16 (2001) 133-137
35. Olive P.L. Cell proliferation as a requirement for development of the contact effect in chinese hamster V79 spheroids. Radiation Res. 117 (1989) 79-92
36. Lutz W.K. In vivo covalent binding of organic chemicals to DNA as a quantitative indicator in the process of chemical carcinogenesis. Mutation Res. 65 (1979) 289-356
37. Lutz W.K. Quantitative evaluation of DNA binding data for risk estimation and for classification of direct and indirect carcinogens. J. Cancer Res. Clin. Oncol. 112 (1986) 85-91
38. Sagelsdorff P., Lutz W.K., and Schlatter C. The relevance of covalent binding to mouse liver DNA to the carcinogenic action of hexachlorocyclohexane isomers. Carcinogenesis 4 (1983) 1267-1273
39. Sagelsdorff P., Lutz W.K., and Schlatter C. DNA methylation in rat liver by daminozide, 2,2-dimethylhydrazine, and dimethylnitrosamine. Fundamental Appl. Toxicol. 11 (1988) 723-730
40. McCann J., Choi E., Yamasaki E., and Ames B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci. U.S.A. 72 (1975) 5135-5139
41. Gentile J.M., Gentile G.J., and Plewa M.J. Mutagenicity of selected aniline derivatives to Salmonella following plant activation and mammalian hepatic activation. Mutation Res. 188 (1987) 185-196
42. Chou M.W., Heflich R.H., and Fu P.P. Metabolism of 1-nitrobenzo(a)pyrene by rat liver microsomes to potent mutagenic metabolites. Carcinogenesis 7 (1986) 1837-1844
43. Hajos A.K.D., and Winston G.W. Dinitropyrene nitroreductase activity of purified NAD(H)-quinone oxidoreductase: role in rat liver cytosol and induction by aroclor-1254 pretreatment. Carcinogenesis 12 (1991) 697-792
44. McGregor D.B., Edwards I., Wolf C.R., Forrester L.M., and Caspary W.J. Endogenous xenobiotic enzyme levels in mammalian cells. Mutation Res. 261 (1991) 29-39
45. Fahrig R., and Engelke M. Reinvestigation of in vivo genotoxicity studies in man. Part I: no induction of DNA strand breaks in peripheral lymphocytes after metronidazole therapy. Mutation Res. 395 (1997) 215-221
46. Touati E., Hofnung M., Thiberge J.M., Michel V., Labigne A., and Jenks P.J. Short-term infection with Helicobacter pylori and 1 week exposure to metronidazole does not enhance gastric mutation frequency in transgenic mice. J. Antimicrobic. Chemother. 46 (2000) 987-992
47. Menéndez D., Rojas E., Herrera L.A., Lopez M.C., Sordo M., Elizondo G., and Ostrosky-Wegman P. DNA breakage due to metronidazole treatment. Mutation Res. 478 (2001) 153-158
48. Suter W., Ahiabor R., Blanco B., Locher F., Mantovani F., Robinson M., Sreenan G., Staedtler F., Swinger T., Vignutelli A., and Perentes E. Evaluation of the in vivo genotoxic potential of three carcinogenic aromatic amines using the BigBlue™ transgenic mouse mutation assay. Environ. Mol. Mutagen. 28 (1996) 354-362
49. Declos K.B., Cerniglia C.E., Dooley K.L., Campbell W.L., Franklin W., and Walker R.P. The role of intestinal microflora in the metabolic activation of 6-nitrochrysene to DNA-binding derivatives in mice. Toxicology 60 (1990) 137-150
50. Sasaki Y.F., Sekihashi K., Izumiyama F., Nishidate E., Saga A., Ishida K., and Tsuda S. The comet assay with multiple mouse organs: comparison of comet assay results and carcinogenicity with 208 chemicals selected from IARC monographs and U.S. NTP carcinogenicity database. Crit. Rev. Toxicol. 30 (2000) 629-799
51. Rickert D.E. Metabolism of Nitroaromatic compounds. Drug Metabol. Rev. 18 (1987) 23-53
52. Rowland R. Factors affecting metabolic activity of the intestinal microflora. Drug Metabol. Rev. 19 (1988) 243-261